2. How is the economic assessment of vaccines performed today?
暂无分享,去创建一个
[1] K. Atkins,et al. Impact of the national rotavirus vaccination programme on acute gastroenteritis in England and associated costs averted , 2017, Vaccine.
[2] B. Standaert,et al. The Sustained Rotavirus Vaccination Impact on Nosocomial Infection, Duration of Hospital Stay, and Age: The RotaBIS Study (2005–2012) , 2016, Infectious Diseases and Therapy.
[3] D. Jamison,et al. Extended Cost-Effectiveness Analysis for Health Policy Assessment: A Tutorial , 2016, PharmacoEconomics.
[4] M. Jit,et al. Methodological Challenges to Economic Evaluations of Vaccines: Is a Common Approach Still Possible? , 2016, Applied Health Economics and Health Policy.
[5] Franziska Wulf,et al. Methods For The Economic Evaluation Of Health Care Programmes , 2016 .
[6] B. Standaert,et al. Medium- to Long-Term Impact of Rotavirus Vaccination on Hospital Care in Belgium: A 7-Year Follow-Up of the Rotavirus Belgium Impact Study (RotaBIS) , 2015, Infectious Diseases and Therapy.
[7] B. Standaert,et al. Cost Analysis of Two Methods for Improving the Quality of Care (Qoc) Scores in Paediatric Hospital Wards During Winter Periods. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[8] Mirjam Knol,et al. Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community , 2015, PharmacoEconomics.
[9] M. Jit,et al. The broader economic impact of vaccination: reviewing and appraising the strength of evidence , 2015, BMC Medicine.
[10] M. Jit,et al. Discounting in the evaluation of the cost-effectiveness of a vaccination programme: A critical review. , 2015, Vaccine.
[11] M. Connolly,et al. Quantifying the broader economic consequences of quadrivalent human papillomavirus (HPV) vaccination in Germany applying a government perspective framework , 2015, Health Economics Review.
[12] B. Standaert,et al. Dissecting the indirect effects caused by vaccines into the basic elements , 2015, Human vaccines & immunotherapeutics.
[13] Christina M Getrich,et al. Catching Up With the HPV Vaccine: Challenges and Opportunities in Primary Care , 2015, The Annals of Family Medicine.
[14] V. Nelen,et al. Exploring the potential impact of rotavirus vaccination on work absenteeism among female administrative personnel of the City of Antwerp through a retrospective database analysis , 2015, BMJ Open.
[15] B. Standaert,et al. Improvement in hospital Quality of Care (QoC) after the introduction of rotavirus vaccination: An evaluation study in Belgium , 2015, Human vaccines & immunotherapeutics.
[16] C. L. Ventola. The antibiotic resistance crisis: part 1: causes and threats. , 2015, P & T : a peer-reviewed journal for formulary management.
[17] J. Zipprich,et al. Measles Outbreak — California, December 2014–February 2015 , 2015, MMWR. Morbidity and mortality weekly report.
[18] P. Bonanni,et al. The intangible benefits of vaccination – what is the true economic value of vaccination? , 2015, Journal of market access & health policy.
[19] M. Toumi,et al. National Immunization Therapeutic Advisory Group: it is time for experience sharing and best practice learning , 2015, Journal of market access & health policy.
[20] J. Höhne,et al. How Do Decision Makers in Europe Value Other Economic Evaluation Tools Than Cost-Effectiveness Analysis for Vaccines? , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[21] Bruce Y. Lee,et al. Reassessing the value of vaccines. , 2014, The Lancet. Global health.
[22] Desmond Curran,et al. Budget constraint and vaccine dosing: a mathematical modelling exercise , 2014, Cost Effectiveness and Resource Allocation.
[23] Fiscal consequences of changes in morbidity and mortality attributed to rotavirus immunisation. , 2013, Vaccine.
[24] Baudouin Standaert,et al. Can a Multi-Criteria Decision (MCD) Optimisation Model Help Decision Makers in the Optimal Selection of Vaccines When Expanding Their Universal Mass Vaccination Programme? The Case of Poland , 2013 .
[25] M. Postma,et al. Economics of vaccines revisited , 2013, Human vaccines & immunotherapeutics.
[26] E. Riedmann,et al. Letter from the Editor , 2013, Human vaccines & immunotherapeutics.
[27] M. Postma,et al. The Impact of Rotavirus Vaccination on Discounted Net Tax Revenue in Egypt , 2012, PharmacoEconomics.
[28] Baudouin Standaert,et al. Selecting a Mix of Prevention Strategies against Cervical Cancer for Maximum Efficiency with an Optimization Program , 2012, PharmacoEconomics.
[29] K. Marsh,et al. Estimating cost-effectiveness in public health: a summary of modelling and valuation methods , 2012, Health Economics Review.
[30] J. Caro,et al. Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[31] Uwe Siebert,et al. Modeling good research practices--overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[32] Mirjam Kretzschmar,et al. Dynamic Transmission Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-5 , 2012, Value in Health.
[33] D. Owens,et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[34] Andy Stergachis,et al. The Role of Cost—Consequence Analysis in Healthcare Decision—Making , 1998, PharmacoEconomics.
[35] D. Canning,et al. Rethinking the benefits and costs of childhood vaccination: the example of the Haemophilus influenzae type b vaccine. , 2011, Vaccine.
[36] David Patrick,et al. Evaluating societal preferences for human papillomavirus vaccine and cervical smear test screening programme , 2010, Sexually Transmitted Infections.
[37] Brian Godman,et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers , 2010, BMC health services research.
[38] Simon G Thompson,et al. Uncertainty and validation of health economic decision models. , 2009, Health economics.
[39] J. Giesecke,et al. Childhood vaccination schedules in Europe vary widely , 2009, Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.
[40] R. Milne,et al. Budget impact and cost-effectiveness of including a pentavalent rotavirus vaccine in the New Zealand childhood immunization schedule. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[41] K. McCaffery,et al. HPV vaccination catch up program - utilisation by young Australian women. , 2009, Australian family physician.
[42] J. Giesecke,et al. Childhood vaccination schedules in Europe vary widely : Is this a problem? (In der Diskussion) , 2009 .
[43] J. Berkhof,et al. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis. , 2008, Vaccine.
[44] U. Desselberger,et al. The Financial Burden of Rotavirus Disease in Four Countries of the European Union , 2008 .
[45] B. Standaert,et al. Estimating utility scores in young children with acute rotavirus gastroenteritis in the UK , 2008, Journal of medical economics.
[46] S. Abdulla,et al. Economic burden of malaria in rural Tanzania: variations by socioeconomic status and season , 2007, Tropical medicine & international health : TM & IH.
[47] M. Drummond,et al. Do we fully understand the economic value of vaccines? , 2007, Vaccine.
[48] Partha Dasgupta,et al. Economics: A Very Short Introduction , 2007 .
[49] D. Canning,et al. Epidemics and Economics , 2006 .
[50] T. Vesikari,et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. , 2006, The New England journal of medicine.
[51] B. Kouyaté,et al. Catastrophic household expenditure for health care in a low-income society: a study from Nouna District, Burkina Faso. , 2006, Bulletin of the World Health Organization.
[52] E. Worrall,et al. Is malaria a disease of poverty? A review of the literature , 2005, Tropical medicine & international health : TM & IH.
[53] W. Gerth,et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[54] D. Heymann,et al. Eradicating polio. , 2004, The New England journal of medicine.
[55] Stephanie R Earnshaw,et al. Integer/linear mathematical programming models: a tool for allocating healthcare resources. , 2003, PharmacoEconomics.
[56] M. Bala,et al. Conditions for the near equivalence of cost-effectiveness and cost-benefit analyses. , 2002, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[57] J. Sachs,et al. The economic and social burden of malaria , 2002, Nature.
[58] Jeremiah Hurley,et al. An Overview of the Normative Economics of the Health Sector , 2000 .
[59] R. Holman,et al. Cost-effectiveness analysis of a rotavirus immunization program for the United States. , 1995, JAMA.
[60] W. Dowdle. The principles of disease elimination and eradication. , 1998, Bulletin of the World Health Organization.
[61] Frank A. Sloan,et al. Valuing health care : costs, benefits, and effectiveness of pharmaceuticals and other medical technologies , 1995 .
[62] C. Farrington. Estimation of vaccine effectiveness using the screening method. , 1993, International journal of epidemiology.
[63] P E Fine,et al. Herd immunity: history, theory, practice. , 1993, Epidemiologic reviews.
[64] P. Steerenberg,et al. Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. , 2010, Annals of the rheumatic diseases.
[65] M R Gillick,et al. Adverse consequences of hospitalization in the elderly. , 1982, Social science & medicine.